Investors Area

Enhancing embryo implantation
Improving women’s fertility

Watch video

Pioneering research

OXOLIFE is developing a drug in a specific field were none has been effective to date, acting directly on the endometrium enhancing embryo implantation and increasing Live Birth Rates

The answer to an unmet medical need

Treatments and technology to boost ovulation and maximize embryo quality are constantly improving, but no treatment has yet been developed that addresses the process of implantation, accounting for 50% of pregnancies lost in IVF cycles.

Oxolife’s technology increases embryo implantation and restores ovulation.

About Oxolife

Oxolife has developed OXO-001, a first-in-class oral drug that directly enhances embryo implantation and increases pregnancy rates. Unlike current treatments addressing only symptoms, OXO-001 targets infertility and is being studied for effectiveness in Polycystic Ovary Syndrome (PCOS), a common endocrine disorder in women.
See more

News

Oxolife and Agnès Arbat Honoured by the European Investment Bank at BIO-EUROPE® 2025.

Celebrating innovation in women’s health and scientific leadership.Our CEO, Agnès Arbat, has been awarded by […]

Read more

Oxolife featured in Femtech Insider

Oxolife has been featured in Femtech Insider  a leading platform spotlighting innovation in women’s health. We […]

Read more

OXOLIFE Confirms the Safety of OXO-001 in Women of Childbearing Age in a Phase I Clinical Trial

OXOLIFE has published the results of a Phase I clinical trial in the International Journal […]

Read more